Search PubMed⌕ Search

Biomedical subjects

R Troiano

Publications and source records attributed to R Troiano.

47 records · Page 3Linked to original sources

Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum.

In this case, rising longitudinal levels of CA125 were significant in the detection of peritoneal papillary serous carcinoma, and led to the indication for surgery. Rising longitudinal CA125 has been shown to be important in the detection of ovarian cancer, but little data exist as to its relevance for the detection of peritoneal papillary serous carcinoma. This rare primary tumor is usually associated with women at high risk for epithelial ovarian carcinoma, although this patient was not at high risk as she had no familial breast or ovarian cancer history.

CA-125 Antigen↗

Direct interaction with cellular targets as the mechanism for chromium carcinogenesis.

The carcinogenic activity of chromium appears to be due to its direct interaction with cellular targets and not to nonspecific solid-state carcinogenesis. Chromium was evaluated at 2 valences, Cr+3 (as CrC13) and Cr+6 (as K2Cr2O7), for its toxicity, transforming activity, and ability to induce chromosomal aberrations in tertiary cultures of mouse fetal cells. The ID50 (dose for 50 percent inhibition of cell growth) of Cr+3 was approximately 4 times greater than that of Cr+6 after 96 h of exposure, and about 29 times greater than that of Cr+6 after 1 h of exposure. At equitoxic concentrations, both chromium valences induced the same degree of morphologic changes and alterations of growth behavior, but Cr+6 produced more chromosomal aberrations. Using autoradiography in an established cloned line of mouse cells, unscheduled DNA synthesis was observed in cells previously exposed to Cr+6 but not in cells previously exposed to Cr+3.

Animals↗

Testing of an Index of Pulmonary Dysfunction in Multiple Sclerosis.

The reliability and validity of an Index of Pulmonary Dysfunction in Multiple Sclerosis (Index) comprised of four readily assessed clinical signs was studied. Forty patients with MS performed pulmonary function testing and underwent clinical evaluation to determine whether or not the Index correctly identified those patients with pulmonary dysfunction. The Index correctly predicted the presence or absence of significant respiratory muscle weakness (defined as Pemax less than 50% of predicted) in 32 (80%) of the subjects. All subjects who had normal expiratory muscle strength (Pemax greater than or equal to 80% of predicted) were correctly classified by the Index; however, not all patients with isolated expiratory muscle weakness were correctly identified. Test-retest reliability, interrater reliability (Spearman rho coefficients of 0.87 and 0.94, respectively), and internal consistency (alpha = .83) of the Index were acceptable. Index scores were not associated with changes in any other PFT results except residual volume, which increased with the severity of respiratory muscle weakness. The Index has acceptable validity and reliability for use in clinical practice to identify those neurological patients with expiratory muscle weakness.

Adult↗